Oncomatryx Biopharma reduces capital by 140,565.60 euros by amortizing treasury shares

The Biscayan biotechnology company Oncomatryx Biopharma, S.A. will reduce its share capital by 140,565.60 euros through the cancellation of 468,552 treasury shares, without any return of contributions to shareholders. The agreement was unanimously adopted by the extraordinary general meeting held on September 16, 2026, and is published in the Official Gazette of the Mercantile Registry (BORME) no. 191, dated October 2, 2026, under official reference BORME-C-2026-5306.

The announcement is formalized in compliance with Article 319 of the Revised Text of the Capital Companies Act, which requires the publication of capital reductions agreed upon by public limited companies. The company’s registered office is located in Derio (Bizkaia), Parque Tecnológico de Bizkaia, 801 B 2º, postal code 48160, with tax identification number A95586780. The announcement appears signed in Derio on September 29, 2026, by the non-director secretary of the board of directors, Luis Alba Ferré.

Terms of the operation

The reduction is executed via the cancellation of treasury shares, with the following parameters:

• Amount of capital reduction: 140,565.60 euros.
• Cancelled shares: 468,552, all of the same class.
• Nominal value of each share: 0.30 euros.
• Origin of the securities: treasury shares, previously acquired by the company through a purchase agreement.
• Return of contributions: none, as the company itself is the holder of the cancelled shares.
• Destination of the difference between acquisition price and nominal value: voluntary reserves, subject to the same requirements as the capital reduction.

The stated purpose of the operation is solely the cancellation of these securities, with no cash return to shareholders.

New share capital and statutory reform

As a result of the agreement, Article 6 of the corporate bylaws is rewritten as follows:

• Share capital: 3,662,911.80 euros.
• Representation: 12,209,706 ordinary, registered shares, with a nominal value of 0.30 euros each.
• Structure: a single class and series, with the same rights and obligations.
• Status: fully subscribed and paid up.

Creditors’ right of opposition

The announcement expressly opens the channel for opposition for the company’s creditors, who may exercise their right within a period of one (1) month from the date of publication, in accordance with Articles 334 and 336 of the Capital Companies Act. This is the standard protection mechanism in capital reductions that do not involve the return of contributions or the offsetting of losses.

Recent company background

The operation is part of an intense sequence of corporate actions. On June 30, 2025, the general meeting of shareholders approved the transformation of Oncomatryx Biopharma, S.L. into a public limited company (sociedad anónima), published in the BORME on July 21, 2025 (BORME-C-2025-4292). Already as a public limited company, on May 25, 2026, the company registered a capital increase of 883,156.50 euros, which raised the subscribed and paid-up capital to 3,803,477.40 euros (BORME-A-2026-103-48, published on June 2, 2026). The now-announced reduction returns that figure to 3,662,911.80 euros.

Regarding corporate governance, the BORME records the appointment in November 2025 of Innvierte Economía Sostenible SICC SME and BBK Fundazioa as directors, as well as Permedika Entrepreneurs, S.L. as managing director, and in February 2026, the fixing of the number of directors at 15. The company also appears as the sole shareholder of Nelum Oncology, S.L., incorporated in 2026 with its registered office in the same technology park.

Impact for investors and creditors

The redemption of treasury shares reduces capital without cash outflow and without altering net equity beyond the adjustment against voluntary reserves, a common formula to simplify the structure following a capital increase. For creditors, the relevant detail is the one-month opposition period; for investors, the new capital figure and the number of outstanding securities, which stand at 12,209,706 shares with a nominal value of 0.30 euros.

Source: Official Gazette of the Mercantile Registry (BORME), no. 191, October 2, 2026, Second Section - Announcements and legal notices (Capital reduction), page 6588 (official reference: BORME-C-2026-5306).